Paper Review Records
All Paper Review Records
10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.
102
days
Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox
AuthorsAikaterini Damianaki; Emelina Stambolliu; Panagiotis Iliakis; Panagiotis Theofilis; Aggeliki Vakka; Evangelia Kalliakouda; Polykarpos Christos Patsalis; Dimitrios Konstantinidis; Dimitrios Petras
Affiliations1. Nephrology Department, Hippokration General Hospital of Athens, Athens, Greece; 2. First Department of Cardiology, National and Kapodistrian University of Athens, Hippokration General Hospital of Athens, Athens, Greece; 3. Department of Medicine, Division of Cardiology, Angiology and Internal Emergency Medicine, 3. Ruhr University Bochum, Knappschaft Kliniken University Hospital Bochum, Bochum, Germany
33
days
Limitations in PAR1-Targeted Screening of Antithrombotic Phytochemicals
AuthorsArienmughare Oghenetega; Nimrah Bhatti; Hira Khalid; Emmanuel Edigberhi; Osamagbe Osaghae; Khurrum Shabbir
Affiliations1. Department of Medicine, University of Benin, Benin City, Nigeria; 2. Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan; 3. Department of Molecular Biology and Genetics, Liaquat University of Medical and Health Sciences, Jamshoro, Pakistan; 4. Department of Medicine, Rawal Institute of Health Sciences, Islamabad, Pakistan
23
days
From Hypothesis-generating to Decision-grade: Making Finerenone–spironolactone Comparisons in HFpEF Globally Implementable
AuthorsM. Vijayasimha; M. Srikanth; Gurjeet Singh
Affiliations1. University Institute of Allied Health Science, Chandigarh University, Gharuan, Mohali, India; 2. Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak, India
91
days
Lipoprotein (a) and Coronary Atherosclerosis in Intracoronary Imaging - YELLOW II – Lp(a) Study
AuthorsChen Gurevitz; Yuliya Vengrenyuk; Shingo Minatoguchi; Keisuke Yasumura; Amit Hooda; Prakash Krishnan; Pedro Moreno; Jagat Narula; Samin Sharma; Robert S. Rosenson; Annapoorna S. Kini
Affiliations1. Metabolism and Lipids Program, The Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, USA; 2. The Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, USA; 3. UTHealth Sciences Center, Houston, USA; 4. Mount Sinai Hospital, New York, USA
93
days
Dapagliflozin Inhibits Thrombin Induced ADAM17 Phosphorylation and Downstream ERK/p-c-Jun-mediated CTGF Induction to Prevent Neointimal Hyperplasia
AuthorsTing-Lin Yen; Po-Ching Chou; Chia-Ti Tsai; Yi-Ling Chen; Chieh-Yu Chen; Yi-Fan Chien; Wen-Chin Ko
Affiliations1. Department of Medical Research, Cathay General Hospital, Taipei City, Taiwan; 2. Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; 3. Division of Interventional Cardiology, Department of Cardiovascular Center, Cathay General Hospital, Taipei City, Taiwan; 4. Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, Taipei City, Taiwan; 5. Division of Cardiac Electrophysiology, Department of Cardiovascular Center, Cathay General Hospital, Taipei City, Taiwan; 6. Division of General Cardiology, Department of Cardiovascular Center, Cathay General Hospital, Taipei City, Taiwan; 7. Department of Internal Medicine, Cathay General Hospital, Taipei City, Taiwan; 8. School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan
17
days
Between Complexity and Translation: A Reflection on Cardiac EV Signaling, Subtype Function, and the Path to Clinical Validation
AuthorsWenbin Lian; Yuangang Qiu
Affiliations1. The First School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China; 2. The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China; 3. Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, China
22
days
Precision Secondary Prevention after Myocardial Infarction: Who Still Benefits from β-Blockade?
AuthorsQiaoqiao Zheng; Yiqun Lou
Affiliations1. Department of Cardiovascular Medicine, XianJu People’s Hospital, Zhejiang Southeast Campus of Zhejiang Provincial People’s Hospital, Affiliated Xianju’s Hospital, Hangzhou Medical College, Xianju Zhejiang, China
67
days
N-Lac-Phe Ameliorates Myocardial Cell Death by Improving Mitochondrial Dysfunction, Ultimately Improving TAC-induced Heart Failure
AuthorsLei Sha; Anning Du; Xiaoying Xu; Zhu Li; Biao Xu; Lina Kang
Affiliations1. Department of Cardiology, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine, Nanjing, China; 2. Department of Cardiology, Affiliated Hospital of Medical School, Nanjing Drum Tower Hospital, Nanjing University, Nanjing, China
54
days
Targeting SIRT3 in Diabetic Cardiomyopathy: Mechanism-Based Therapeutic Strategies
AuthorsXiaofang Zhang; Hui Lin; Xinrou Yu; Tiantian Lu; Jun Wang; Hui Ji; Dihua Huang; Dajun Lou
Affiliations1. Department of Endocrinology, Shaoxing People’s Hospital, The First Affiliated Hospital of Shaoxing University, Shaoxing, China; 2. School of Medicine, Shaoxing University, Shaoxing, China; 3. Department of Cardiology, The Affiliated Lihuili Hospital of Ningbo University, Ningbo, China; 4. Department of Cardiology, Zhuji Affiliated Hospital of Wenzhou Medical University, Shaoxing, China; 5. Department of Pharmacy, Shaoxing People’s Hospital, Shaoxing, China
57
days
The 2025 ESC/EAS Dyslipidaemia Focused Update: Clinical Interpretation and Practical Implications
AuthorsLuca Bonanni; Ada Cutolo; Nicola Ferri
Affiliations1. Department of Medicine, Venice, Italy; 2. Department of Medicine, University of Padova, Padova, Italy; 3. Department of Cardiology, Venice, Italy
Expert Matching · Case Demo
Turn Your Submission Goalsinto a Verifiable Journal Plan
Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.
Client
I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?
CrushSCI
Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.
- Suggested title
- Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment
- Database shortlist
- Environmental Technology & Innovation
SampleLatest 5 valid paper samples from 2026
Average review96.4 days
Median77 days